Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Biomed Mater Res B Appl Biomater ; 112(6): e35434, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38874589

ABSTRACT

Bioactive degradable scaffolds that facilitate bone healing while fighting off initial bacterial infection have the potential to change established strategies of dealing with traumatic bone injuries. To achieve this a composite material made from calcium phosphate graphene (CaPG), and MXene was synthesized. CaPG was created by functionalizing graphene oxide with phosphate groups in the presence of CaBr with a Lewis acid catalyst. Through this transformation, Ca2+ and PO4 3- inducerons are released as the material degrades thereby aiding in the process of osteogenesis. The 2D MXene sheets, which have shown to have antibacterial properties, were made by etching the Al from a layered Ti3AlC2 (MAX phase) using HF. The hot-pressed scaffolds made of these materials were designed to combat the possibility of infection during initial surgery and failure of osteogenesis to occur. These two failure modes account for a large percentage of issues that can arise during the treatment of traumatic bone injuries. These scaffolds were able to retain induceron-eluting properties in various weight percentages and bring about osteogenesis with CaPG alone and 2 wt% MXene scaffolds demonstrating increased osteogenic activity as compared to no treatment. Additionally, added MXene provided antibacterial properties that could be seen at as little as 2 wt%. This CaPG and MXene composite provides a possible avenue for developing osteogenic, antibacterial materials for treating bone injuries.


Subject(s)
Anti-Bacterial Agents , Calcium Phosphates , Graphite , Osteogenesis , Tissue Scaffolds , Titanium , Osteogenesis/drug effects , Graphite/chemistry , Graphite/pharmacology , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Titanium/chemistry , Titanium/pharmacology , Tissue Scaffolds/chemistry , Calcium Phosphates/chemistry , Calcium Phosphates/pharmacology , Animals , Humans , Escherichia coli/drug effects , Staphylococcus aureus/drug effects , Staphylococcus aureus/growth & development
2.
Proc Natl Acad Sci U S A ; 120(45): e2309156120, 2023 Nov 07.
Article in English | MEDLINE | ID: mdl-37903261

ABSTRACT

Cobalt-containing alloys are useful for orthopedic applications due to their low volumetric wear rates, corrosion resistance, high mechanical strength, hardness, and fatigue resistance. Unfortunately, these prosthetics release significant levels of cobalt ions, which was only discovered after their widespread implantation into patients requiring hip replacements. These cobalt ions can result in local toxic effects-including peri-implant toxicity, aseptic loosening, and pseudotumor-as well as systemic toxic effects-including neurological, cardiovascular, and endocrine disorders. Failing metal-on-metal (MoM) implants usually necessitate painful, risky, and costly revision surgeries. To treat metallosis arising from failing MoM implants, a synovial fluid-mimicking chelator was designed to remove these metal ions. Hyaluronic acid (HA), the major chemical component of synovial fluid, was functionalized with British anti-Lewisite (BAL) to create a chelator (BAL-HA). BAL-HA effectively binds cobalt and rescues in vitro cell vitality (up to 370% of cells exposed to IC50 levels of cobalt) and enhances the rate of clearance of cobalt in vivo (t1/2 from 48 h to 6 h). A metallosis model was also created to investigate our therapy. Results demonstrate that BAL-HA chelator system is biocompatible and capable of capturing significant amounts of cobalt ions from the hip joint within 30 min, with no risk of kidney failure. This chelation therapy has the potential to mitigate cobalt toxicity from failing MoM implants through noninvasive injections into the joint.


Subject(s)
Arthroplasty, Replacement, Hip , Hip Prosthesis , Humans , Hip Prosthesis/adverse effects , Hyaluronic Acid , Dimercaprol , Chelation Therapy , Prosthesis Failure , Arthroplasty, Replacement, Hip/adverse effects , Metals , Cobalt , Chelating Agents/therapeutic use , Ions
3.
ACS Appl Bio Mater ; 5(12): 5608-5616, 2022 12 19.
Article in English | MEDLINE | ID: mdl-36383154

ABSTRACT

Wound dressings have been shifting toward a more active role in the wound-healing process. Hydrated environments with additives to aid in the healing process are currently being explored through the application of hydrocolloid dressings. However, these moist healing environments are also ideal for bacterial growth, leading to the widespread use of antibiotics with concerns of antibiotic resistance and toxicity. To overcome this concern, we present a hydrogel wound dressing consisting of hyaluronic acid (HA) cross-linked with gentamicin. This hydrogel treats bacterial infection locally, lowering the effective dose and reducing the concerns of antibiotic resistance and systemic exposure. Changing the cross-linking density, by using varied amounts of a cross-linker, created gels that provided a sustained release of gentamicin for up to 9 days with a range of adhesive and cohesive properties. Overall, this HA hydrogel could provide an important solution in treating local infection in burns and other dermal injuries.


Subject(s)
Hyaluronic Acid , Hydrogels , Hydrogels/therapeutic use , Hyaluronic Acid/pharmacology , Bandages, Hydrocolloid , Anti-Bacterial Agents/therapeutic use , Gentamicins
SELECTION OF CITATIONS
SEARCH DETAIL